



Editorial

# Special Issue “Physiology and Pathophysiology of Placenta 2.0”

Giovanni Tossetta

Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy;  
g.tossetta@univpm.it

We are pleased to present this Special Issue of the *International Journal of Molecular Sciences*, entitled “Physiology and Pathophysiology of Placenta 2.0”.

The development of a normal and functional placenta is essential for correct fetal development. Thus, placentation is a key process that is tightly regulated. The placenta is a temporary but essential organ with different and fundamental functions during pregnancy [1–3]. Placental development is regulated by several factors such as growth factors, hormones, and many other types of molecules that control placental cell proliferation, differentiation, migration, and invasion [4,5].

This multitude of factors involved in placental development influence (either activating or inhibiting) several signaling pathways involved in the expression of specific genes necessary for a successful pregnancy. The importance of normal placental development becomes evident when this process is impaired, leading to severe pregnancy complications [6] such as preeclampsia (PE), fetal growth restriction (FGR) [7], gestational trophoblastic diseases (GTD) [8], preterm delivery [9], and gestational diabetes mellitus (GDM) [10]. Pregnancy can also be altered by exogenous agents such as bacteria, viruses, chemicals, and natural compounds that can impair the normal placental functions, thus altering pregnancy outcome. Many of the pregnancy complications previously mentioned are associated with an increase in maternal and fetal mortality and morbidity, and can cause life-long health complications for both mother and child.

Important signaling pathways such as TGF $\beta$ /SMAD, PI3K/AKT/mTOR, and JAK/STAT have been reported to be impaired in a number of pregnancy complications such as PE, GDM, and FGR [11–13]. Furthermore, normal placental development can be altered by viral and bacterial infections during pregnancy that can cause preterm delivery or result in significant neonatal complications [14,15]. All pregnancy complications mentioned are characterized by systemic inflammation, a known process involved in endothelial dysfunction [16–21].

An early diagnosis is crucial for a better outcome of most severe diseases in humans [22–24]. Since an early diagnosis of pregnancy complications can significantly improve pregnancy outcome, research is always looking for new specific biomarkers able to allow an early diagnosis of these pregnancy complications [10,25–28].

It is interesting to note that several natural and synthetic compounds showed beneficial effects in treating pregnancy complications [29,30], suggesting a possible use of these compounds for the treatment/prevention of these diseases.

Thus, a better knowledge of the mechanisms involved in the regulation of human placenta development under both normal and pathological conditions may bring new perspectives in the treatment of these pregnancy complications.

The aim of this Special Issue is to provide an overview of the physiology and Pathophysiology of the placenta in order to better understand its development under normal and pathological conditions.

**Conflicts of Interest:** The author declares no conflicts of interest.



**Citation:** Tossetta, G. Special Issue “Physiology and Pathophysiology of Placenta 2.0”. *Int. J. Mol. Sci.* **2024**, *25*, 4586. <https://doi.org/10.3390/ijms25094586>

Received: 14 April 2024

Accepted: 19 April 2024

Published: 23 April 2024



**Copyright:** © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## References

- Tossetta, G.; Fantone, S.; Piani, F.; Crescimanno, C.; Ciavattini, A.; Giannubilo, S.R.; Marzoni, D. Modulation of NRF2/KEAP1 Signaling in Preeclampsia. *Cells* **2023**, *12*, 1545. [[CrossRef](#)] [[PubMed](#)]
- Marzoni, D.; Crescimanno, C.; Zaccheo, D.; Coppari, R.; Underhill, C.B.; Castellucci, M. Hyaluronate and CD44 expression patterns in the human placenta throughout pregnancy. *Eur. J. Histochem.* **2001**, *45*, 131–140. [[CrossRef](#)] [[PubMed](#)]
- Tossetta, G.; Avellini, C.; Licini, C.; Giannubilo, S.R.; Castellucci, M.; Marzoni, D. High temperature requirement A1 and fibronectin: Two possible players in placental tissue remodelling. *Eur. J. Histochem.* **2016**, *60*, 2724. [[CrossRef](#)] [[PubMed](#)]
- Marzoni, D.; Fiore, G.; Giordano, A.; Nabissi, M.; Florio, P.; Verdenelli, F.; Petraglia, F.; Castellucci, M. Placental expression of substance P and vasoactive intestinal peptide: Evidence for a local effect on hormone release. *J. Clin. Endocrinol. Metab.* **2005**, *90*, 2378–2383. [[CrossRef](#)] [[PubMed](#)]
- Muhlhäuser, J.; Marzoni, D.; Morroni, M.; Vuckovic, M.; Crescimanno, C.; Castellucci, M. Codistribution of basic fibroblast growth factor and heparan sulfate proteoglycan in the growth zones of the human placenta. *Cell Tissue Res.* **1996**, *285*, 101–107. [[CrossRef](#)] [[PubMed](#)]
- Fantone, S.; Giannubilo, S.R.; Marzoni, D.; Tossetta, G. HTA family proteins in pregnancy outcome. *Tissue Cell* **2021**, *72*, 101549. [[CrossRef](#)] [[PubMed](#)]
- Cardaropoli, S.; Paulesu, L.; Romagnoli, R.; Ietta, F.; Marzoni, D.; Castellucci, M.; Rolfo, A.; Vasario, E.; Piccoli, E.; Todros, T. Macrophage migration inhibitory factor in fetoplacental tissues from preeclamptic pregnancies with or without fetal growth restriction. *Clin. Dev. Immunol.* **2012**, *2012*, 639342. [[CrossRef](#)] [[PubMed](#)]
- Marzoni, D.; Quaranta, A.; Lorenzi, T.; Morroni, M.; Crescimanno, C.; De Nictolis, M.; Toti, P.; Muzzonigro, G.; Baldi, A.; De Luca, A.; et al. Expression pattern alterations of the serine protease HtrA1 in normal human placental tissues and in gestational trophoblastic diseases. *Histol. Histopathol.* **2009**, *24*, 1213–1222. [[CrossRef](#)] [[PubMed](#)]
- Cecati, M.; Sartini, D.; Campagna, R.; Biagini, A.; Ciavattini, A.; Emanuelli, M.; Giannubilo, S.R. Molecular analysis of endometrial inflammation in preterm birth. *Cell Mol. Biol.* **2017**, *63*, 51–57. [[CrossRef](#)] [[PubMed](#)]
- Tossetta, G.; Fantone, S.; Gesuita, R.; Di Renzo, G.C.; Meyyazhagan, A.; Tersigni, C.; Scambia, G.; Di Simone, N.; Marzoni, D. HtrA1 in Gestational Diabetes Mellitus: A Possible Biomarker? *Diagnostics* **2022**, *12*, 2705. [[CrossRef](#)]
- Li, Y.; Yan, J.; Chang, H.M.; Chen, Z.J.; Leung, P.C.K. Roles of TGF-beta Superfamily Proteins in Extravillous Trophoblast Invasion. *Trends Endocrinol. Metab.* **2021**, *32*, 170–189. [[CrossRef](#)] [[PubMed](#)]
- Villalobos-Labra, R.; Silva, L.; Subiabre, M.; Araos, J.; Salsoso, R.; Fuenzalida, B.; Saez, T.; Toledo, F.; Gonzalez, M.; Quezada, C.; et al. Akt/mTOR Role in Human Foetoplacental Vascular Insulin Resistance in Diseases of Pregnancy. *J. Diabetes Res.* **2017**, *2017*, 5947859. [[CrossRef](#)] [[PubMed](#)]
- Alijotas-Reig, J.; Esteve-Valverde, E.; Ferrer-Oliveras, R.; Llurba, E.; Gris, J.M. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. *Clin. Rev. Allergy Immunol.* **2017**, *53*, 40–53. [[CrossRef](#)] [[PubMed](#)]
- Licini, C.; Tossetta, G.; Avellini, C.; Ciarmela, P.; Lorenzi, T.; Toti, P.; Gesuita, R.; Voltolini, C.; Petraglia, F.; Castellucci, M.; et al. Analysis of cell-cell junctions in human amnion and chorionic plate affected by chorioamnionitis. *Histol. Histopathol.* **2016**, *31*, 759–767. [[CrossRef](#)] [[PubMed](#)]
- Tossetta, G.; Fantone, S.; Delli Muti, N.; Balercia, G.; Ciavattini, A.; Giannubilo, S.R.; Marzoni, D. Preeclampsia and severe acute respiratory syndrome coronavirus 2 infection: A systematic review. *J. Hypertens.* **2022**, *40*, 1629–1638. [[CrossRef](#)] [[PubMed](#)]
- Mateuszuk, L.; Campagna, R.; Kutryb-Zajac, B.; Kus, K.; Slominska, E.M.; Smolenski, R.T.; Chlopicki, S. Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. *Biochem. Pharmacol.* **2020**, *178*, 114019. [[CrossRef](#)] [[PubMed](#)]
- Szczesny-Malysiak, E.; Stojak, M.; Campagna, R.; Grosicki, M.; Jamrozik, M.; Kaczara, P.; Chlopicki, S. Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium. *Oxid. Med. Cell Longev.* **2020**, *2020*, 4678252. [[CrossRef](#)] [[PubMed](#)]
- Campagna, R.; Mateuszuk, L.; Wojnar-Lason, K.; Kaczara, P.; Tworzydlo, A.; Kij, A.; Bujok, R.; Mlynarski, J.; Wang, Y.; Sartini, D.; et al. Nicotinamide N-methyltransferase in endothelium protects against oxidant stress-induced endothelial injury. *Biochim. Biophys. Acta Mol. Cell Res.* **2021**, *1868*, 119082. [[CrossRef](#)] [[PubMed](#)]
- Zapotoczny, B.; Braet, F.; Kus, E.; Ginda-Makela, K.; Klejevskaja, B.; Campagna, R.; Chlopicki, S.; Szymonski, M. Actin-spectrin scaffold supports open fenestrae in liver sinusoidal endothelial cells. *Traffic* **2019**, *20*, 932–942. [[CrossRef](#)] [[PubMed](#)]
- Tossetta, G.; Piani, F.; Borghi, C.; Marzoni, D. Role of CD93 in Health and Disease. *Cells* **2023**, *12*, 1778. [[CrossRef](#)] [[PubMed](#)]
- Campagna, R.; Vignini, A. NAD(+) Homeostasis and NAD(+) Consuming Enzymes: Implications for Vascular Health. *Antioxidants* **2023**, *12*, 376. [[CrossRef](#)] [[PubMed](#)]
- Togni, L.; Mascitti, M.; Sartini, D.; Campagna, R.; Pozzi, V.; Salvolini, E.; Offidani, A.; Santarelli, A.; Emanuelli, M. Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review. *Biomolecules* **2021**, *11*, 1594. [[CrossRef](#)] [[PubMed](#)]
- Campagna, R.; Pozzi, V.; Spinelli, G.; Sartini, D.; Milanese, G.; Galosi, A.B.; Emanuelli, M. The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update. *Biomolecules* **2021**, *11*, 1214. [[CrossRef](#)] [[PubMed](#)]
- Sartini, D.; Campagna, R.; Lucarini, G.; Pompei, V.; Salvolini, E.; Mattioli-Belmonte, M.; Molinelli, E.; Brisigotti, V.; Campanati, A.; Bacchetti, T.; et al. Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. *Hum. Cell* **2021**, *34*, 1929–1931. [[CrossRef](#)] [[PubMed](#)]

25. Gesuita, R.; Licini, C.; Picchiassi, E.; Tarquini, F.; Coata, G.; Fantone, S.; Tossetta, G.; Ciavattini, A.; Castellucci, M.; Di Renzo, G.C.; et al. Association between first trimester plasma htra1 level and subsequent preeclampsia: A possible early marker? *Pregnancy Hypertens.* **2019**, *18*, 58–62. [[CrossRef](#)] [[PubMed](#)]
26. Giannubilo, S.R.; Licini, C.; Picchiassi, E.; Tarquini, F.; Coata, G.; Fantone, S.; Tossetta, G.; Ciavattini, A.; Castellucci, M.; Giardina, I.; et al. First trimester HtrA1 maternal plasma level and spontaneous preterm birth. *J. Matern. Fetal Neonatal Med.* **2022**, *35*, 780–784. [[CrossRef](#)]
27. Piani, F.; Agnoletti, D.; Baracchi, A.; Scarduelli, S.; Verde, C.; Tossetta, G.; Montaguti, E.; Simonazzi, G.; Degli Esposti, D.; Borghi, C.; et al. Serum uric acid to creatinine ratio and risk of preeclampsia and adverse pregnancy outcomes. *J. Hypertens.* **2023**, *41*, 1333–1338. [[CrossRef](#)] [[PubMed](#)]
28. Piani, F.; Tossetta, G.; Fantone, S.; Agostinis, C.; Di Simone, N.; Mandala, M.; Bulla, R.; Marzoni, D.; Borghi, C. First Trimester CD93 as a Novel Marker of Preeclampsia and Its Complications: A Pilot Study. *High Blood Press. Cardiovasc. Prev.* **2023**, *30*, 591–594. [[CrossRef](#)] [[PubMed](#)]
29. Bacchetti, T.; Campagna, R.; Sartini, D.; Cecati, M.; Morresi, C.; Bellachoma, L.; Martinelli, E.; Rocchetti, G.; Lucini, L.; Ferretti, G.; et al. C. spinosa L. subsp. rupestris Phytochemical Profile and Effect on Oxidative Stress in Normal and Cancer Cells. *Molecules* **2022**, *27*, 6488. [[CrossRef](#)] [[PubMed](#)]
30. Tossetta, G.; Fantone, S.; Giannubilo, S.R.; Marzoni, D. The Multifaced Actions of Curcumin in Pregnancy Outcome. *Antioxidants* **2021**, *10*, 126. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.